Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus

Table 3

Adverse events in 39 SLE patients receiving rituximab.

Total adverse events, % (𝑛)	17.9 (7)
Infusion reaction (rash, fever, myalgia)	10.3 (4)
Infection (pneumonia, tuberculosis, abscess)	7.7 (3)
Death due to severe infection, % (𝑛)	2.7 (1)

*Values are % (number) of patients.